Alprostadil - Taiwan Liposome Company

Drug Profile

Alprostadil - Taiwan Liposome Company

Alternative Names: Alprostadil nanoemulsion - Taiwan Liposome Company; PGE1 - Taiwan Liposome Company; ProFlow; Prostaglandin E1 - Taiwan Liposome Company

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator Taiwan Liposome Company
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders

Most Recent Events

  • 05 Apr 2017 Launched for Diabetic neuropathies, Peripheral arterial disorders and Diabetic foot ulcer in Taiwan (IV) (Taiwan Liposome Company pipeline, April 2017)
  • 28 Aug 2014 Clinical trials in Diabetic foot ulcer in South Korea (IV)
  • 28 Aug 2014 Clinical trials in Diabetic neuropathies in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top